Description
HGH Fragment 176-191 is the natural unmodified 15-amino-acid C-terminal fragment of human growth hormone (hGH), corresponding to positions 177-191 of the mature hGH sequence. Unlike intact hGH which activates the GH receptor and downstream IGF-1 axis, the C-terminal fragment is studied as a “lipolytic-selective” sequence that engages metabolic and adipose tissue pathways without the broader anabolic and insulin-modulating consequences of GH receptor activation. The compound has been investigated in preclinical research for adipocyte biology, fatty acid oxidation, lipolysis pathways, and metabolic energy expenditure across both cell-culture and rodent obesity research models. HGH Fragment 176-191 contains the characteristic intramolecular disulfide bridge between Cys6 and Cys13 of the fragment sequence (corresponding to Cys182 and Cys189 of native hGH), considered structurally important for its bioactivity.
Benefits (Research Focus)
• Lipolytic-selective signaling — studied for adipose tissue research without IGF-1 axis or glucose-modifying activity
• Fatty acid oxidation — investigated for β-oxidation pathway endpoints in adipocyte and metabolic models
• Adipocyte biology — explored for hormone-sensitive lipase (HSL) activation and lipolysis markers
• Energy expenditure research — examined for mitochondrial function and metabolic rate endpoints
• Comparative GH pharmacology — researched for receptor-pathway differentiation versus full-length growth hormone
What Researchers Look At
• Adipocyte receptor interaction and downstream signaling cascade activation
• Hormone-sensitive lipase (HSL) activity and intracellular lipolysis markers
• Comparative pharmacology versus full-length hGH (IGF-1, insulin sensitivity, glucose homeostasis)
• Adipose tissue mass and body composition endpoints in DIO rodent models
• Structural comparison to AOD-9604 (Tyr-modified analog of the same C-terminal region)
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 5 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: HGH Fragment 176-191
• Synonyms: HGH Frag 176-191; hGH(177-191); Growth Hormone Fragment 176-191
• Class: Natural C-terminal hGH fragment; lipolytic-selective peptide; 15 amino acids
• Sequence: Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (LRIVQCRSVEGSCGF)
• Modification: Native unmodified sequence; intramolecular disulfide bridge between Cys6 and Cys13 of the fragment
• Formula / M.W.: C75H121N23O22S2, ~1716.07 g/mol (verify against batch COA)
• Related Compound: AOD-9604 (CAS 221231-10-3) — the same C-terminal region with N-terminal tyrosine substitution
⚠️ Disclaimer
This product is intended for laboratory research use only.
Not for human or veterinary use.
Not approved for diagnostic, therapeutic, or medical applications.
Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• Frag 176-191 Batch COA — October 30, 2025
• Frag 176-191 VPeptide — May 4, 2026